NEW YORK, Oct. 27 (GenomeWeb News) - Shares in Third Wave Technologies were down 16.3 percent in early-afternoon trading as investors slammed the company despite beating top-line projections for the third quarter.

 

Third Wave's stock was trading down $1.30 at $6.70 on the Nasdaq exchange after nosediving to $5.97 in 30 minutes of heavy trading after the market opened.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.